Hematopoietic growth factors, version 1.2020: Featured updates to the NCCN guidelines

Pamela Sue Becker, Elizabeth A. Griffiths, Laura M. Alwan, Kimo Bachiashvili, Anna Brown, Rita Cool, Peter Curtin, Shira Dinner, Ivana Gojo, Ashley Hicks, Avyakta Kallam, Wajih Zaheer Kidwai, Dwight D. Kloth, Eric H. Kraut, Daniel Landsburg, Gary H. Lyman, Ryan Miller, Sudipto Mukherjee, Shiven Patel, Lia E. PerezAdam Poust, Raajit Rampal, Rachel Rosovsky, Vivek Roy, Hope S. Rugo, Sepideh Shayani, Sumithira Vasu, Martha Wadleigh, Kelly Westbrook, Peter Westervelt, Jennifer Burns, Jennifer Keller, Lenora A. Pluchino

Research output: Contribution to journalArticlepeer-review

16 Scopus citations

Abstract

Management of febrile neutropenia (FN) is an integral part of supportive care for patients undergoing cancer treatment. The NCCN Guidelines for Hematopoietic Growth Factors provide suggestions for appropriate evaluation, risk determination, prophylaxis, and management of FN. These NCCN Guidelines are intended to guide clinicians in the appropriate use of growth factors for select patients undergoing treatment of nonmyeloid malignancies. These NCCN Guidelines Insights highlight important updates to the NCCN Guidelines regarding the incorporation of newly FDA-approved granulocyte-colony stimulating factor biosimilars for the prevention and treatment of FN.

Original languageEnglish (US)
Pages (from-to)12-22
Number of pages11
JournalJNCCN Journal of the National Comprehensive Cancer Network
Volume18
Issue number1
DOIs
StatePublished - 2020

ASJC Scopus subject areas

  • Oncology

Fingerprint

Dive into the research topics of 'Hematopoietic growth factors, version 1.2020: Featured updates to the NCCN guidelines'. Together they form a unique fingerprint.

Cite this